Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
about
Dangerous liaisons: how the immune system deals with factor VIIIEpitope mapping factor VIII A2 domain by affinity-directed mass spectrometry: residues 497-510 and 584-593 comprise a discontinuous epitope for the monoclonal antibody R8B12.New insights and therapeutics for immune-mediated thrombocytopenia.Antiphospholipid antibodies: paradigm in transition.New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies.Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat.Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIIIThe IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors.Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.Factor VIII gene variants and inhibitor risk in African American hemophilia A patientsHematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor.AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in miceA major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A.Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.Treatment of acquired hemophilia A.Inhibitor development in haemophilia B: an orphan disease in need of attention.Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunityQuantitation of anti-factor VIII antibodies in human plasma.Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.Risk factors for inhibitor formation in haemophilia: a prevalent case-control study.Inhibitors of factor VIII in black patients with hemophiliaImmune tolerance induction in haemophilia: evidence and the way forward.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceEngineering less immunogenic and antigenic FVIII proteins.Gene therapy for immune tolerance induction in hemophilia with inhibitors.Therapeutic Apheresis in Hematologic, Autoimmune and Dermatologic Diseases With Immunologic Origin.Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics.Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.Immune status of patients with haemophilia A before exposure to factor VIII: first results from the HEMFIL study.IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII.Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.Use of affinity-directed liquid chromatography-mass spectrometry to map the epitopes of a factor VIII inhibitor antibody fraction.Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A.
P2860
Q27000818-0E72C8CE-1EC9-473E-94F7-5C5A87FB2E35Q33240894-0263DA94-8876-4741-96F6-8DDB2862CB4CQ33377901-71A21A86-DCF7-4ED0-B9BA-610BB00E1B68Q33382848-C888AC3B-D151-4526-BF02-19517B4D0358Q33387735-C47FA682-395A-4A86-90A5-3412265EC766Q33469732-D778F76B-8B72-4061-922C-C32F6DAB61C8Q33552218-9BFEC26C-6106-4F0D-9328-3A73954114D9Q34550081-2922FC9C-6709-4743-AD06-18DBAEA6B42CQ35046770-5FF2DEFB-A7C3-4942-88B0-83574B9CA712Q35168244-21D1274D-50A9-417C-89BB-C43D4A493141Q35953537-5F996D51-0080-4586-A10E-C5212150C7EBQ36059597-BC69ABA8-3BAB-4ABF-80A8-4B8479749A04Q36174626-DA631D27-4038-48B5-A583-B079A4457C0DQ36203308-799A94BB-260F-4E9B-8D3F-6120F4197A41Q36250957-4540D57D-6310-42B5-8280-059F29EF5114Q36473047-E1CD80A8-1BC4-485D-8F2E-7E35EFD2036AQ36571141-D3B4F9A2-D848-4301-A66C-755FEB726B62Q36643868-D745DA2D-C9D3-4EE1-94C6-A3980035CAA5Q36661807-91A132FD-DB3E-43F3-8B2E-2A8B24AC7A68Q36802699-1979912F-88C3-4ABF-B91A-04EAA47234D6Q36872038-29C0DE44-583E-493F-8BD9-B16C51D45D5FQ36915859-AFA1FCD5-3262-48CB-95CF-8938593B2FF8Q37129689-F1285EF5-7A17-464A-B7D8-32133122D7F3Q37316242-223F0E0A-504A-44B8-B46F-DAA865B5CFE4Q37325682-979DD85E-7636-4A0B-8024-CFE60CF1B376Q37385316-14433221-35B7-4833-BB81-44C5791EC47FQ37903944-6F354B77-462B-4FDB-899D-4B4538095827Q38101041-18089253-6FB4-475A-90A8-AB06485BDA72Q38632876-EF6D6AFE-5F04-41AB-B7EE-128D71BBF7C3Q38803022-0BC9F25F-3187-48E0-AD58-2708ED4536B2Q38955520-5871A76D-E2B0-4BBF-98A8-C6A0853174BFQ39174749-759700D1-DA30-4B69-A9D4-D729AA9CC82AQ39600375-AEB5C713-D270-449A-A4EB-C8E568543B67Q40072633-21341D5F-75BD-48A3-A18F-456D16E39044Q40086660-7BFF6A95-9AB8-4090-9075-59B9E90A5E41Q41821071-F13F1BDE-B7F1-4A11-AA7A-9E6CDC1A6AB7Q41924275-71C3F897-477C-4CBE-A090-682CD97DDA2BQ42096639-84C3D156-380B-4C73-95D5-3CB08C6A9D03Q42864630-9BDEFE17-3544-4ED6-8348-A032C00C87E2Q42975417-12278EAC-D4A7-4312-8569-480A8992C627
P2860
Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
@ast
Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
@en
type
label
Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
@ast
Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
@en
prefLabel
Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
@ast
Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
@en
P2860
P1476
Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
@en
P2093
P2860
P304
P356
10.1111/J.1538-7836.2004.00802.X
P577
2004-07-01T00:00:00Z